First, we found that in a mouse model of erlotinib-resistant lung cancer in which tumors do not regress upon treatment with the TKI, low numbers and functionally impaired CD4 and CD8 lymphocytes are found similar to untreated tumors even following TKI treatment. Here, CD4 is linked to lung cancer.